This week we're re-launching our regular update on the latest notable private placements that went free-trading in the past few days. Read on for all the details.
Note: PrivatePlacements.com has NOT received compensation from any of the companies listed below in connection with this message, nor is the writer an investor in any company listed.
1. Alpha Cognition Inc. (TSX-V: ACOG)
- Gross proceeds: US$2.01
- Number of units: 9.14 million
- Unit type: Special units
- Price per unit: US$0.22
- Closing date: 12/22/23
- Today's share price (Jan. 15): $0.68
- Deal appreciation: ~126.7%
- Warrants: Half
- Strike Price: $0.31
- Expiry date: 08/31/26
Company breakdown:
Alpha Cognition is a biopharmaceutical company focused on neurodegenerative diseases. Its flagship is ALPHA 1062, an oral therapy designed to reduce side effects and improve patient outcomes for Alzheimer's. Shares of the company jumped back in December after it announced the FDA had accepted its drug application for ALPHA 1062 for treating mild to moderate Alzheimer's. It closed the fourth and final tranche of the above private placement shortly after.
